Shanghai Argo Biopharma has entered into two exclusive agreements with Novartis, securing a $185 million upfront payment and potential total deal value of $4.165 billion to develop RNAi therapies.

Information on the Target

Shanghai Argo Biopharma is a prominent biotechnology company specializing in the development of RNA interference (RNAi) therapies designed to treat various diseases. Established with the vision of harnessing the power of RNAi technology, Argo has made significant strides in advancing its therapeutic platforms, leading to innovative solutions in the biomedical field. The company focuses on creating effective treatments that can profoundly impact patient care.

With a robust pipeline of candidates, Argo is well-positioned to leverage its expertise in RNAi therapy. The recent collaboration with Novartis marks a significant milestone in its journey, showcasing both its scientific capabilities and commercial potential in the evolving landscape of biopharmaceuticals.

Industry Overview in China

The biotechnology sector in China has experienced remarkable growth over the past decade, supported by government initiatives and increased investment in research and development. RNAi technology, in pa